Dr. Michael Schymura

Economics of AI & Innovation
Back to Home
Updated: Feb 22
Chemical Industry Radar

November 2025

Published December 8, 2025 by Dr. Michael Schymura

2.5/10
Bearish
-0.5
Industry Sentiment Index (1 = crisis, 10 = euphoria)
Red Alert: Structural Rupture in the Sector

The mood in the German chemical industry has shifted from chronic concern to acute existential alarm. The VCI warns of a "knock-out" phase for domestic production. Massive layoffs at Wacker (1,500) and Bayer (12,000), the Covestro acquisition by ADNOC, and persistently high energy costs define the month.

1.Executive Summary

From chronic concern to acute existential alarm

2.5
Deeply Negative
-0.5 from October

The "Mood" Index: November 2025

From chronic concern to acute existential alarm

The sentiment permeating the German chemical and pharmaceutical industry in November 2025 has shifted from chronic concern to acute existential alarm. The term "crisis" no longer adequately captures the structural rupture currently unfolding across the sector.

The defining mood of the month is captured by the Verband der Chemischen Industrie (VCI) in their third-quarter report, which explicitly warns of a "knock-out" phase for domestic production. This terminology marks a significant escalation in rhetoric, moving from warnings about competitiveness to warnings about survival.

The prevailing sentiment in boardrooms from Ludwigshafen to Leverkusen is one of resignation regarding domestic growth prospects. Capital allocation strategies are increasingly defensive regarding Germany ("Standort D") while remaining offensive regarding expansion in the United States and China.

Key Indicators at a Glance

Production Q3

-1.5%

Year-over-year (VCI)

Capacity Utilization

~70%

Below profitability threshold

Energy Cost Gap

3-4x

vs. US Gulf Coast

Global Growth

+2.9%

While Germany shrinks

The Global Decoupling

This domestic contraction stands in sharp contrast to the global projection of +2.9% growth in chemical production, driven by China (+5.0%), India (+3.0%), and South Korea (+3.0%). Germany is not just growing slower; it is shrinking while the rest of the world expands.

Top 3 Headline Events

1

Covestro-ADNOC Deal Clears EU Foreign Subsidies Hurdle

In a landmark decision, the European Commission granted conditional approval for ADNOC to acquire Covestro AG. Valued at approximately €15 billion, this represents the largest takeover of a German chemical company in recent history. The approval under the Foreign Subsidies Regulation (FSR) confirmed that ADNOC benefited from unlimited state guarantees which distorted the acquisition process.

Strategic Implications

  • •Sets precedent for FSR application in European industrial M&A
  • •Signals strategic shift of Western technology leaders to capital-rich state funds
  • •Covestro stock pegged to takeover price (~€62), effectively exiting active equity story
2

VCI Q3 Report: The "Knock-out" Warning

On November 11, 2025, the VCI released its quarterly report presenting a bleak statistical reality. Production fell 0.3% quarter-on-quarter and sits 1.5% below prior year. The hoped-for second-half recovery has failed to materialize. The sector would need 10% revenue growth just to reach nominal 2019 levels.

Strategic Implications

  • •Explicit warning of "knock-out" phase for domestic production
  • •Full-year 2025 production forecast: -2.0%
  • •Political remedies viewed as "patchwork" rather than structural solutions
3

Wacker & Bayer Announce Massive Workforce Reductions

November brought the crisis home to the workforce. Wacker Chemie announced 1,500 job cuts primarily at German sites, targeting €300M in annual savings. Simultaneously, Bayer has cut ~12,000 jobs globally under its "Dynamic Shared Ownership" restructuring. These announcements shatter the illusion that specialty chemicals or life sciences are immune to location factors.

Strategic Implications

  • •Wacker retreating to semiconductor-grade polysilicon and specialty silicones
  • •Cost-cutting has moved from operational efficiency to structural downsizing
  • •Evidence that the "transformation" narrative is being overtaken by "rationalization"

Strategic Conclusions

Capital Allocation

  • →Defensive regarding Germany (Standort D)
  • →Offensive regarding US and China expansion
  • →Transformation overshadowed by rationalization

Political Reality

  • →Grid fee subsidies 2026: band-aid, not solution
  • →Gap between Green Deal and industrial reality never wider
  • →Structural guarantees for CapEx decisions absent

2.Macroeconomic & Regulatory Landscape

Energy, Policy, and the Structural Dilemma

The fundamental uncompetitiveness of German energy costs remains the central wound of the chemical industry. In November 2025, the discussion moved beyond the volatility of spot prices to the structural reality of grid fees and levies that keep the delivered cost of power to German industry significantly above international peers.

The Energy Cost Reality

Electricity Costs Germany

Industrial Power 2024
15-18 ct/kWh
vs. USA
3-4x higher
vs. China
2-3x higher
Grid Fees Trend
Rising

Despite subsidies

Gas & Feedstock Dynamics

Price Level
Stabilized at 'new normal'
LNG vs. Pipeline
Permanent disadvantage

vs. US ethane crackers

China Dumping
Overcapacity crushing margins

Grid Fee Politics: The 2026 Subsidy

In late November, the Bundesrat approved a federal measure to subsidize transmission grid fees with €6.5 billion from the Climate and Transformation Fund (KTF) for 2026. This intervention is designed to stabilize the non-energy components of electricity prices.

Industry Reaction: Lukewarm at best. Associations like the VCI and theEnergieintensive Industrien (EID) criticize the measure for lacking long-term certainty. A one-year subsidy does not provide planning security for 20-year investment cycles typical in chemical plant engineering.

The industry continues to demand a "Brückenstrompreis" (bridge electricity price) capped at 4-6 ct/kWh—a demand the federal government has rejected in favor of piecemeal subsidies.

VCI Q3 2025: Anatomy of Contraction

MetricQ3 vs Q2 2025Q3 vs Q3 2024Strategic Implication
Production-0.3%-1.5%Recovery flatlined; structural capacity closures
Total Sales-1.5%-2.3%Revenue falling faster than volume; pricing power lost
Producer Prices+0.1%-1.8%Deflationary pressure; cannot pass on costs
Capacity Utilization~70%—Below 80% profitability threshold

Full Year 2025 Forecast: VCI expects chemical production to decline by 2.0%, with total sales falling to €221 billion (-1.0%).

Producer Prices

-1.8%

October 2025 vs. October 2024 (Destatis)

Eighth consecutive month of decline

New Orders

+1.1%

September month-over-month

But 3-month trend still negative (-3.0%)

Policy Watch: Berlin & Brussels

CO2 Storage Act (CCS)

Positive

On November 6, the Bundestag approved the Carbon Storage Act, finally creating a legal framework for CCS/CCU in Germany. For the chemical industry with unavoidable process emissions, this is crucial enabling technology.

Impact: Positive long-term, but infrastructure is years away. Requires transport networks to offshore storage sites.

EU Foreign Subsidies Regulation

Mixed

The Commission's FSR application to the Covestro deal sets precedent. By forcing ADNOC to remove unlimited state guarantees, the EU signals rigorous policing of the 'level playing field' for M&A.

Impact: Adds complexity to exit strategies for European industrial assets. May cool state-backed investor interest.

'Bureaucracy Heart Attack' Warning

Negative

On November 5, the VCI issued a stark warning about 'Bürokratieinfarkt.' The cumulative burden of CSRD, Supply Chain Due Diligence Act, and REACH requirements is absorbing massive corporate resources.

Impact: For many Mittelstand chemical companies, compliance costs are becoming a barrier to remaining in business.

The 'Implementation Gap'

Negative

Despite high-level summits and joint declarations, industry leaders express deep frustration. While the diagnosis (high costs, high bureaucracy) is agreed upon, the therapy is stuck in administrative gridlock.

Impact: Capital allocation decisions cannot wait for political consensus. Investment is flowing elsewhere.

"The gap between political ambition (the Green Deal) and industrial reality (uncompetitive operating costs) has never been wider."

— Industry Association Analysis, November 2025

3.Corporate Movers & Shakers

Portfolio Rationalization, Defensive Cost-Cutting, and Active M&A

The strategic landscape of the German chemical giants in November 2025 is defined by portfolio rationalization, defensive cost-cutting, and active M&A. The "Big Players" are actively reshaping themselves to survive a prolonged period of European stagnation.

BASF SE: The Ludwigshafen Accord

BASF SE

BAS.DE
Restructuring

IPO Preparation for Agricultural Solutions

  • •Preparing potential IPO for Agricultural Solutions division
  • •November 21: Inaugurated new production line in Nanjing, China
  • •Silence on new major investments in Ludwigshafen

Outlook: Outperformer potential with Agrar-IPO value unlocking.

China vs. Germany Investment

In China

New Nanjing dispersants line. Continued massive CapEx flow toward Asian growth markets.

In Germany

Ludwigshafen in optimization/maintenance mode. No new major investments announced.

Under Severe Pressure

Wacker Chemie AG

WCH.DE
Restructuring

Caught in the Solar Storm

  • •Announced 1,500 job cuts targeting €300M savings
  • •Battling high German energy costs + Chinese solar dumping
  • •Cost base correction deemed essential for survival

Outlook: Market read job cuts as distress signal. Moving from growth to defensive posture.

Evonik Industries AG

EVK.DE
Weak Quarter

Efficiency over Growth

  • •Reported 'weak third quarter' reflecting construction/auto malaise
  • •Stock down 10.5% in November on earnings miss
  • •Doubling down on 'Next Generation Solutions'

Outlook: Investors disappointed 'specialty' nature didn't offer more protection.

Relative Resilience

Evonik Industries AG

EVK.DE
Weak Quarter

Efficiency over Growth

  • •Reported 'weak third quarter' reflecting malaise
  • •Doubling down on 'Next Generation Solutions'

Outlook: Weak quarter, but specialty focus intact.

Henkel AG

HEN3.DE
Stable

The Consumer Hedge

  • •Sales growth acceleration; outlook reaffirmed
  • •Capitalizing on 'lipstick effect'
  • •€1 billion share buyback program

Outlook: Stable. Strong cash flow. Consumer exposure provides buffer against industrial headwinds.

Merck KGaA

MRK.DE
Growth Mode

Life Science & Tech Focus

  • •Completed $3.4 billion SpringWorks acquisition
  • •Process Solutions and Semiconductor Solutions to drive growth
  • •Betting on AI boom material needs

Outlook: Different cycle\u2014pharma and semiconductors. Expanding while others cut.

Strategic Divergence Summary

Expanding

  • Merck: Taiwan semiconductor site + AI
  • Henkel: Consumer resilience + innovation
  • Brenntag: Aggressive M&A in US/UK

Restructuring

  • BASF: Ludwigshafen accord, frozen growth
  • Evonik: 2,000 jobs, admin decimation
  • Wacker: PACE program, 1,500 cuts

Distressed / Exiting

  • Covestro: Sold to ADNOC (81.77%)
  • DOMO: Insolvency filed Dec 30
  • INEOS: Rheinberg closures, 450 jobs

4.Innovation & Transformation

Green Chemistry Between Ambition and Reality

The current crisis is forcing a bifurcation in innovation: projects with immediate efficiency gains or those subsidized by the state are proceeding, while speculative "green" projects without a clear business case are stalling.

The Hydrogen Reality Check

Germany's Hydrogen Ambitions Face Harsh Reality

Reports surfaced in late November indicating that the German hydrogen market is developing significantly slower than political targets suggest. The "core network" infrastructure rollout is facing delays, and the cost gap between green hydrogen and fossil gas remains unbridgeable without massive, continuous subsidies.

Green Hydrogen (Electrolysis)

Delayed

Companies hesitant to sign 10-year offtake agreements for expensive green hydrogen when their own production futures in Germany are uncertain.

  • •EWE constructing 320 MW hydrogen plant in Emden—proceeding, but broader adoption lagging
  • •Cost gap vs. natural gas remains prohibitive without continuous subsidies
  • •Infrastructure rollout (core network) facing significant delays

Verdict: Market development far behind political targets. Commercial viability elusive.

Turquoise Hydrogen (Methane Pyrolysis)

On Track

BASF's collaboration with ExxonMobil on methane pyrolysis advancing as pragmatic alternative.

  • •Uses existing natural gas infrastructure—lower transition costs
  • •Produces hydrogen + solid carbon, avoiding CO2 emissions
  • •Does not require massive renewable electricity loads of electrolysis
  • •'Technology-open' approach gaining favor as pragmatic path

Verdict: Promising alternative for industrial hydrogen. Gaining momentum.

Biomass and the Circular Economy

Biomass Initiative

Critical

A critical report emerged highlighting the 'failure' of Germany's biomass initiative to boost the chemical industry.

  • •Despite high-profile investments (UPM biorefinery in Leuna), scaling faltering
  • •Logistic complexities and high biomass costs vs. petrochemicals
  • •Wood-based chemicals proving economically unviable at scale
  • •Bio-economy remains niche rather than steam cracker replacement

Verdict: Biomass will remain marginal in near term. Not the structural solution hoped for.

Mass Balance Approach

On Track

BASF secured ISCC EU certification for biomass-balanced methanol portfolio in November.

  • •Feed bio-waste into existing plants, mathematically attribute green content
  • •'Drop-in' solution: works with existing infrastructure
  • •Only commercially viable path for green chemicals in current environment
  • •Allows gradual transition without massive capital outlays

Verdict: Proving to be the only economically viable path forward. Expect wider adoption.

Technology & Innovation Highlights

Nobel Prize Validation: MOFs

The global recognition of Metal-Organic Frameworks (MOFs) with the Nobel Prize in Chemistry (December 10) highlighted German industrial leadership.

BASF has been a pioneer in scaling MOF production for CO2 capture and industrial applications. This proves that R&D engines in Germany are still capable of world-class innovation, even if production economics are challenged.

Automotive Tech: trinamiX

trinamiX (a BASF subsidiary) announced it will unveil new biometric driver-monitoring technology at CES 2026.

This underscores the strategic shift toward high-value functional components(sensors, optics) where German engineering can still command a premium over commodity chemicals.

Carbon Capture & Storage (CCS)

Bundestag Approval (Nov 6): The Carbon Storage Act finally creates a legal framework for CCS/CCU in Germany. For the chemical industry with unavoidable process emissions, this is crucial enabling technology for decarbonization.

Reality Check: The infrastructure to transport captured CO2 to storage sites (likely offshore in the North Sea) is still years away. The legislative progress is necessary but not sufficient for near-term impact.

The Innovation Bifurcation

Proceeding

  • →Mass balance approach (BASF certified)
  • →Methane pyrolysis / turquoise hydrogen
  • →High-value tech components (sensors, optics)
  • →MOFs and advanced materials

Stalling

  • →Large-scale green hydrogen without subsidy
  • →Biomass-based chemical scaling
  • →Speculative "green" projects without clear ROI
  • →Projects requiring new German CapEx commitment

5.Financial Radar

Stock Performance, Valuations, and the Flight from Cyclicals

The capital markets in November 2025 delivered a clear verdict: investors are fleeing cyclical, energy-intensive German assets. With the exception of special situations (Covestro) or defensive plays (Henkel, BASF dividend yield), the sector significantly underperformed the DAX.

Sector Overview

Sector YTD

-8.3%

STOXX Chemicals

Average P/E

14.2x

vs. 18x historical

Dividend Yield

4.1%

Big 5 average

EV/EBITDA

7.8x

Cyclical trough

November 2025 Stock Performance

BASFBAS.DE

Outperformer. Over 5% dividend yield + potential value unlocking from Agricultural Solutions IPO. 'Too cheap to ignore' thesis.

+2.8%
HenkelHEN3.DE

Defensive anchor. Share buyback program and steady consumer demand provided a floor. Insulated from industrial rout.

Stable
BayerBAYN.DE

Volatile. Historic lows (P/E about 4x). Slight uptick reflects short covering and hope that accelerated cuts improve cash flow. Deep skepticism on debt and litigation.

+0.8%
Covestro1COV.DE

Pegged to takeover price (around 62 Euro). Now an arbitrage play awaiting ADNOC deal closure. Decoupled from fundamental sentiment.

Flat
WackerWCH.DE

Negative. Job cut announcement read as distress signal rather than efficiency. Solar pricing exposure a major drag.

-5.2%
EvonikEVK.DE

Deep red. Sharp sell-off following Q3 earnings miss. Investors capitulating on hope for construction recovery in 2025.

-10.5%
LanxessLXS.DE

Crisis level. Profit warning and 'no light at end of tunnel' commentary decimated the stock. High leverage concerns. Most shorted in sector.

-12.1%

Analyst Sentiment: The Sell Side Capitulation

November 2025 marked a turning point in analyst sentiment, moving from wait and see to sell.

Deutsche Bank

Prolonged Downturn Warning

  • -Major sector report warning of existential crisis for parts of European chemical industry
  • -Slashed price targets across the board
  • -Notable: Evonik cut from 16 Euro to 13 Euro
J.P. Morgan

Longest Downcycle on Record

  • -Downgraded European chemical distributors
  • -Maintained cautious stance on producers
  • -Structural headwinds prevent V-shaped recovery

Consensus View: The Value Trap Thesis

The banking sector has abandoned the narrative of a cyclical recovery in H2 2025. The consensus is now pricing in an L-shaped stagnation.

Many German chemical stocks are viewed as value traps - cheap on multiples but structurally impaired on cash flow generation due to uncompetitive energy costs.

Investment Thesis Summary

Potential Upside

  • -BASF: Dividend yield + IPO catalyst
  • -Henkel: Consumer stability + buybacks
  • -Merck: Different cycle (pharma/semi)

Special Situations

  • -Covestro: Arb play, pegged to 62 Euro
  • -Bayer: Deep value if litigation clears

Avoid / Short

  • -Lanxess: Leverage + no visibility
  • -Wacker: Solar exposure, China dumping
  • -Evonik: Construction cycle dependent

The VCI prediction of a 2025 without a happy end appears to be the most accurate forecast for the coming winter. Unless the German government upgrades the Grid Fee Subsidy to a comprehensive Industrial Power Price, the exodus of capital expenditure will accelerate.

- Radar Conclusion, November 2025
Currently Reading

1.Executive Summary

Chapters
Reading Progress

1 of 5

Monthly Briefing
October 2025
3.0
November 2025Now
2.5
December 2025
2.3
January 2026
2.8
Browse all editions →
Back to Projects
All ProjectsResearch Dossiers